Clinical trial for non-small cell lung cancer (NSCLC)

University of the Sunshine Coast has begun a clinical trial evaluating a potential treatment for non-small cell lung cancer (NSCLC). If you have patients aged 18 years or older who have locally advanced NSCLC that has not responded to previous therapies, or metastatic non-squamous NSCLC (Stage III-IV), they may be eligible to participate in the trial.

The trial will be overseen by Principal Investigator Dr Brenton Seidl at Sunshine Coast Haematology and Oncology Clinic (SCHOC) and supported by our experienced clinical trials staff.

We are seeking applications from people who:

• are aged 18 years or older
• have locally advanced NSCLC, that has not responded to therapy or metastatic non-squamous NSCLC at screening (Stage III-IV NSCLC)
• can attend regular visits at our Buderim clinic, located within SCHOC.

If you have any patients who fit the criteria and would be suitable for a clinical trial, we would appreciate your consideration of their participation and, if appropriate, invite them to contact us for further information.

Please do not hesitate to call 0421 964 895 for further information. We will be happy to provide you with flyers to distribute to anyone who might be interested in participating.

Full title: A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations.

This trial has been reviewed by an Australian independent human research ethics committee.